Abstract
AbstractLactic acid bacteria are the well acknowledged probiotics that can cure a variety of diseases. In this study, we observed the in vivo potentials of Pediococcus to treat hyperglycemia, hypercholesterolemia and gastrointestinal infections. A total of 77 Lactobacillus were isolated from the milk of 10 cows and 10 goats, four of those strains inhibited both carbohydrates-hydrolyzing enzymes, α-glucosidase, and α-amylase. They all showed antagonistic effects on pathogenic E. coli and S. Typhimurium which were confirmed by performing pathogen challenge test and visualizing on Electron microscopy. 16S rRNA gene sequence identified that all four strains belong to Pediococcus genus which were further distinguished as Pediococcus acidilactici by pheS gene sequence. Whole genome sequence analysis revealed their non-pathogenic properties for human and the presence of probiotic genes responsible for stress resistance, immunomodulation, adhesion, metal and drug resistance. In vivo trial with diabetes-induced mice ascertained that all Pediococcus acidilactici had significant potentials to reduce elevated glucose and low-density lipoprotein level in blood. Interestingly, two out of four strains were significantly more effective (p < 0.0001 each) than metformin in reducing the blood glucose level. This in vivo study demonstrated that Pediococcus acidilactici might be a promising probiotic to prevent hyperglycemia, hypercholesterolemia and gastrointestinal infections.
Publisher
Springer Science and Business Media LLC
Reference69 articles.
1. International Diabetes Federation (2019) IDF Diabetes Atlas. (International Diabetes Federation, Berlin, 2019).
2. Zhou, B. et al. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4·4 million participants NCD Risk Factor Collaboration (NCD-RisC)*. https://doi.org/10.1016/S0140-6736(16)00618-8 (2016).
3. Seuring, T., Archangelidi, O., Suhrcke, M., Archangelidi, O. & Suhrcke, M. The economic costs of type 2 diabetes: A global systematic review. Pharmacoeconomics. https://doi.org/10.1007/s40273-015-0268-9 (2015).
4. WHO. Global Report on Diabetes. Isbn 978, 6–86 (2016).
5. Poovitha, S. & Parani, M. In vitro and in vivo α-amylase and α-glucosidase inhibiting activities of the protein extracts from two varieties of bitter gourd (Momordica charantia L.). BMC Complement. Altern. Med. 16, 185 (2016).
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献